OK, I officially promise never to quote Barbra’s songs again . . .but, with the 2011 BIO International Convention just a mere three weeks ago – it seems like a distant memory for some of us and a blur for sleep-deprived others. BioWorld Today provided full coverage of the best breakout sessions, tweeted madly and blogged about everything from the Agony of de Feet to Four Days Later: The De-Evolution of a #2011BIO Attendee. But did you know we also shot video of your friends and colleagues along with a few high-profile folks?
Check out our interview with Nigel Gaymond, the chief executive of the UK’s BioIndustry Association, in which he lays out the state of the UK biotech sector.
We also chatted with Keith A. Katkin, president and CEO of Avanir Pharmaceuticals about his company’s newly approved drug Nuedexta, the first and only FDA-approved treatment for pseudobulbar affect.
BIO’s President and CEO, James C. Greenwood, shared BIO’s legislative goals.
We also posted video of BioWorld’s session, Starting up Biotechs in the New Normal World, featuring a lively discussion about the post-2008 world of venture financing by panelists Stuart Collinson, CEO of Tioga Pharmaceuticals Inc.; Walter Ogier, president and CEO of Acetylon Pharmaceuticals Inc.; Art Pappas, managing partner of Pappas Ventures; and Edward Tenthoff, senior research analyst with Piper Jaffray Ventures.
But that’s just a handful of our video offerings. We stopped dozens of conference attendees in the hallways to get their thoughts on the #BIO2011 experience. Check out the full playlist to relive the misty watercolor conference memories (sorry!).